复方苍豆丸阻断食管癌前病变研究  

Clinical Study on Treatment of Esophageal Precancerous Lesion with Cangdouwan Pill

作　　者：侯浚[1] 陈志峰[1] 李绍森[1] 李中元[1] 阎付荣[1] 

机构地区：[1]河北省肿瘤研究所,河北省磁县肿瘤防治所,河北省涉县肿瘤防治所

出　　处：《中国肿瘤临床》1996年第2期117-120,共4页Chinese Journal of Clinical Oncology

基　　金：卫生部科学基金

摘　　要：自１９８８年１１月至１９９３年１１月在食管癌高发区河北省磁县和涉县８个乡进行食管脱落细胞学拉网普查，共查出食管上皮细胞重度增生患者６４８例。全部患者随机分为治疗组和对照组，治疗组口服复方苍豆丸，对照组服用安慰剂。服药５年后根据细胞学复查和食管癌发病登记结果统计，治疗组食管癌变率７．１％，对照组１３．０％，Ｐ＜０．０５。治疗组５年食管癌变率比对照组降低４５．３％。本研究结果提示复方苍豆丸有一定防癌作用。分析影响疗效提高的主要因素是重增Ⅱ级和高年龄患者。Six hundred and forty-eight cases of marked epithelial,hyperplasia diagnosed with esophageal exfoliative cytology were closely followed in the high incidence areas(Ci-xian and Shexian counties)of esophageal cancer. All these cases were randomized divided into the therapeutic group and the control group.For five years,the former group were treated with Cangdouwan Pill while the latter group were given placebo.The results re-examined by cyto-smears showed that the incidence of the esophageal cancer in therapeutic and control group were 7. 1% and 12.9% respectively(P<0. 05). It suggests that Cangdouwan Pill might be of some effect as an anti-cancer preventive medicine.

关 键 词：食管 癌前病变 中草药治疗 中医药疗法 

分 类 号：R273.510.5[医药卫生—中西医结合]